Find a Doctor
Colleen Veloski, MD
Locations: Moffitt Cancer Center
Cancer Focus: Adrenal Carcinoma, Neuroendocrine Tumor , Thyroid Cancer
Dr. Veloski received her MD degree from Medical College of Pennsylvania. She completed an Internal Medicine Residency and Endocrinology Fellowship at Temple University Hospital, Philadelphia, Pennsylvania. Following her Fellowship, Dr. Veloski became an Assistant Professor at Temple University School of Medicine, Section of Endocrinology, and she was promoted to Associate Professor in 2009. Dr. Veloski most recently has been an Associate Professor at Fox Chase Cancer Center, where she served as Director of the Endocrinology and Thyroid Program. Dr. Veloski has extensive experience in the care of cancer patients with endocrine diseases, specializing in the evaluation and treatment of patients with thyroid nodules and thyroid cancer. She holds the Endocrine Certification in Neck Ultrasound. Dr. Veloski’s research interests include the role of molecular markers and genomic testing in thyroid cancer diagnosis, preoperative risk assessment, and treatment.
Education & Training
- Endocrinology, Diabetes & Metabolism
- Internal Medicine
- Temple University Hospital - Endocrinology
- Temple University Hospital - Internal Medicine
- Medical College of Pennsylvania - MD
- Hernandez-Prera J, Valderrabano P, Creed J, de la Iglesia JV, Slebos R, Centeno BA, Tarasova V, Hallanger-Johnson J, Veloski C, Otto KJ, Wenig BM, Yoder S, Lam C, Park DS, Anderson AR, Raghunand N, Berglund A, Caudell J, Gerke TA, Chung CH. Molecular Determinants of Thyroid Nodules with Indeterminate Cytology and RAS Mutations. Thyroid. 2020 Aug.31(1):36-49. Pubmedid: 32689909.
- Wei S, Veloski C, Sharda P, Ehya H. Performance of the Afirma genomic sequencing classifier versus gene expression classifier: An institutional experience. Cancer Cytopathol. 2019 Sep.127(11):720-724. Pubmedid: 31536167.
- Godwin JL, Jaggi S, Sirisena I, Sharda P, Rao AD, Mehra R, Veloski C. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer. J Immunother Cancer. 2017 May.5:40. Pubmedid: 28515940. Pmcid: PMC5433051.
- Sznol M, Postow MA, Davies MJ, Pavlick AC, Plimack ER, Shaheen M, Veloski C, Robert C. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treat Rev. 2017 Jul.58:70-76. Pubmedid: 28689073.
- Ginzburg S, Reddy M, Veloski C, Sigurdson E, Ridge JA, Azrilevich M, Kutikov A. Papillary Thyroid Carcinoma Metastases Presenting as Ipsilateral Adrenal Mass and Renal Cyst. Urol Case Rep. 2015 Nov.3(6):221-222. Pubmedid: 26793559. Pmcid: PMC4714304.
- Tomaszewski JJ, Uzzo RG, Egleston B, Corcoran AT, Mehrazin R, Geynisman DM, Ridge JA, Veloski C, Kocher N, Smaldone MC, Kutikov A. Coupling of prostate and thyroid cancer diagnoses in the United States. Ann Surg Oncol. 2015 Mar.22(3):1043-1049. Pubmedid: 25205302. Pmcid: PMC4419700.
- Hall MJ, Innocent J, Rybak C, Veloski C, Scott WJ, Wu H, Ridge JA, Hoffman JP, Borghaei H, Turaka A, Daly MB. Bilateral granulosa cell tumors: a novel malignant manifestation of multiple endocrine neoplasia 1 syndrome found in a patient with a rare menin in-frame deletion. Appl Clin Genet. 2015 Feb.8:69-73. Pubmedid: 25733923. Pmcid: PMC4337709.
- Lango M, Flieder D, Arrangoiz R, Veloski C, Yu JQ, Li T, Burtness B, Mehra R, Galloway T, Ridge JA. Extranodal extension of metastatic papillary thyroid carcinoma: correlation with biochemical endpoints, nodal persistence, and systemic disease progression. Thyroid. 2013 Sep.23(9):1099-1105. Pubmedid: 23421588. Pmcid: PMC3770240.
The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive
different surveys, and the volume of responses will vary by question.
Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.
We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.
Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.Learn more about our patient comments
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:
- The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
- He or she may be a researcher or other type of provider that does not see patients.
- The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.